Attralus
Latest round
- Series B
Last raised
- Jan 2024
Total raised
- $198M
Investors
- 10
About Attralus
Based in California, US, and founded in 2019 by co-founders Dr. Jonathan Wall and Spencer Guthrie, Attralus, Inc., operates as a biopharmaceutical company that develops immunotherapies and an imaging diagnostic platform used for treating systemic amyloid diseases by removing existing amyloid deposits in the organs and tissues., and Jake Bauer to the Board of Directors Attralus specializes in the research and development of immunotherapies such as the pan-amyloid removal (PAR) therapeutics, designed to eliminate toxic, disease-causing amyloid in organs, and tissues of patients with systemic amyloidosis. The PAR therapeutic approach targets the underlying disease in all types of systemic amyloidosis. Attralus plans to advance its pipeline of transformational pan-amyloid removal (PAR) therapeutics into clinical trials. The first PAR therapeutic, AT-03, is expected to begin a Phase 1 biodistribution study in patients with systemic amyloidosis. It also plans to advance the AT-01 clinical program, which uses amyloid radiotracer to detect all types of amyloid deposits in major organs such as the heart, kidney, liver, and spleen.
Who invested in Attralus
10 investors across 3 rounds
See all investors in Attralus
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Attralus
Who invested in Attralus?
Attralus has 10 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Attralus raised?
Attralus has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Attralus last raise money?
Attralus's most recent round on record is a Series B, in Jan 2024.
What does Attralus do?
Based in California, US, and founded in 2019 by co-founders Dr.
Where is Attralus headquartered?
Attralus is headquartered in South San Francisco, US.
Which VCs invest in companies like Attralus?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Attralus's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Attralus? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.